SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb to a fresh yearly high and move back above a key round-number level is driving attention, with traders celebrating the breakout and bullish momentum. Others question whether the advance can hold, citing resistance, patent-cliff concerns and the lack of a clear new catalyst ahead of the quarterly report.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Attention centers on expectations for Lillys upcoming quarterly report, with traders looking for continued Mounjaro and Zepbound growth and stronger guidance after a recent run to record highs. Bulls see momentum continuing, while skeptics argue expectations are elevated and debate whether oral GLP-1 competition from Novo and Foundayo could challenge Lillys lead.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras investigational treatment for menopausal hot flashes: traders are weighing its positive Phase 2 results and additional clinical data presented at a menopause conference. The reaction is broadly bullish, reinforced by new analyst coverage, but some say the news may already be priced in and emphasize that further trials are needed to confirm the findings.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRAIMFINZI combination drew attention after Phase 3 results showed a substantial survival benefit in first-line extensive-stage small-cell lung cancer. Traders see the data as a potential growth driver and a boost to Amgens oncology pipeline, while debating how much it could add to the business.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts upcoming quarterly report is the dominant focus, with traders watching Azure growth and whether AI demand can justify rising data-center spending. Views are split between confidence in cloud and AI momentum and concern that heavy capex, delayed returns, and depreciation could pressure margins.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A sharp rebound and breakout in Atlassian shares, supported by strong cloud growth and repeated analyst upgrades, has fueled bullish momentum and renewed optimism about software stocks ability to benefit from AI. Traders are divided over whether the move can continue or is overextended ahead of earnings, with some warning of a pullback and persistent concerns about valuation and AI disruption.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxon is drawing attention as crude prices rise amid Middle East supply concerns and traders anticipate a strong refining contribution to its upcoming quarterly report. The community is debating whether refining strength can offset weaker upstream results and how long the margin boost will last.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Traders are focused on Brazils presidential runoff and the possibility of Flvio Bolsonaro winning, with speculation that a change in government could bring more shareholder-friendly policies and lift Petrobras shares. Bullish election positioning is tempered by uncertainty about the result and the risk of a sell-the-news reaction; higher oil prices are also supporting the discussion.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is dominating the discussion after reports that Papa Johns largest U.S. franchisee joined Irth Capitals bid; traders see the added backing as potentially strengthening the deal, but no completed transaction is confirmed. Many remain frustrated that the board rejected earlier offers as weak sales, lower guidance and the dividend suspension weigh on confidence in the standalone turnaround.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons breakout to record highs is drawing attention, with traders pointing to firm crude prices and supply-risk concerns while positioning ahead of its earnings report. Sentiment is mostly bullish, though some question whether strong energy markets will last and whether the rally has already priced in the results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Implied Volatility Surging for ANI Pharmaceuticals Stock Options

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.read more...

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals, Inc. Profit Climbs In Q2

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) revealed earnings for its second quarter that Increases, from the same period last year...

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors

Equity

Bullish Sentiment

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani dismissed the impact of tariffs on the company, stating that over 90% of the total revenues come from finished goods manufactured in the U.S.“While we await the administration's pharmaceutical industry-specific framework, it is worth reiterating ANI's long-standing commitment to the U.S. Pharmaceutical industry and our positive and unique positioning relative to our peers,” the CEO said during the earnings call on Friday. “Products representing less than 5% of our total company revenues rely directly on imports from China. In addition, we have a strong balance sheet that enables us to carry healthy levels of finished goods and raw material inventories.”On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANIP">ANIP</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1334/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_08_at_12_37_09_PM_png_c2361a1206.webp" alt="ANIP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 8, 2025 | Source: Stocktwits" width="1334" height="128"><figcaption>ANIP's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is “practically” 100% American-produced and based to help pacify any government demands.<stembedurl>https://stocktwits.com/Dy2ski/message/624331368</stembedurl>ANI Pharmaceuticals on Friday reported second-quarter net revenues of $211.4 million, representing year-over-year growth of 53.1%, and above an analyst estimate of $190.11 million, according to Fiscal AI data. The company attributed the increase in revenue to a doubling in net revenues from its rare diseases product segment to $104 million. Adjusted and diluted earnings per share came in at $1.80, above an expected $1.42. &nbsp;&nbsp;&nbsp;&nbsp;The company also raised its full-year guidance. ANI now expects full year net revenue of $818 million to $843 million and adjusted EPS of $6.98 to $7.35. The firm added that it expects its rare diseases portfolio to represent about 50% of its total net revenue in 2025.Piper Sandler analyst David Amsellem subsequently raised the firm's price target on ANI Pharmaceuticals to $94 from $80 while keeping an ‘Overweight’ rating on the shares.ANIP stock is up by 49% this year and by about 46% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-procures-rideshare-permit-in-texas/chrnKvjRd4I">Tesla Procures Rideshare Permit In Texas: Retail Expects Stock To Trade Over $330 Until Next Major Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ANI said it expects full-year net revenue of $818 million to $843 million and adjusted EPS of $6.98 to $7.35.

Vanguard Group, Inc. - Vanguard U.S. Multifactor ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$72.61
Prev Close	$73.75
Open	$73.30
Dividend Yield	0.00%
50-Day Moving Average	$73.44
Beta	0.58
Avg. Volume	421,052.56
PE Ratio	15.67

52-Week High	$96.57
52-Week Low	$69.58
Market Capitalization	$1.67B
EPS (Annual)	$3.32
Price to Book	2.79
Revenue Per Employee	$910,686.60

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANIP Fundamentals